Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$23.08 -0.4%	$24.79	$22.64 ▼ $53.96	$1.09B	0.77	497,082 shs	1.27 million shs
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CVAC CureVac	$5.38 -0.4%	$4.24	$2.37 ▼ $5.72	$1.21B	2.49	812,708 shs	770,383 shs
GOSS Gossamer Bio	$1.25 -3.8%	$1.16	$0.66 ▼ $1.55	$284.13M	1.85	1.46 million shs	26.05 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	0.00%	-6.03%	-9.98%	-18.82%	-42.34%
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	+4.25%
CVAC CureVac	0.00%	-1.10%	+16.20%	+80.54%	+59.88%
GOSS Gossamer Bio	0.00%	-13.19%	+10.62%	+6.84%	+33.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPH Amphastar Pharmaceuticals	4.2664 of 5 stars	3.1	2.0	0.0	3.7	1.5	4.2	1.3
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	4.6603 of 5 stars	4.1	5.0	0.0	4.8	1.7	0.0	1.3
GOSS Gossamer Bio	3.7022 of 5 stars	3.5	1.0	0.0	4.7	2.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	2.25	Hold	$32.33	40.09% Upside
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
CVAC CureVac	2.20	Hold	$6.83	27.01% Upside
GOSS Gossamer Bio	3.00	Buy	$7.33	486.67% Upside

Current Analyst Ratings Breakdown

Latest GOSS, CVAC, CALT, and AMPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	CVAC CureVac	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00 ➝ $5.50
6/13/2025	CVAC CureVac	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$7.00 ➝ $5.00
6/12/2025	CVAC CureVac	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
6/12/2025	CVAC CureVac	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/28/2025	CVAC CureVac	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$10.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/12/2025	AMPH Amphastar Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$45.00 ➝ $30.00
5/8/2025	AMPH Amphastar Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $35.00
4/30/2025	CVAC CureVac	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
4/17/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$731.97M	1.49	$5.01 per share	4.61	$15.23 per share	1.52
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
CVAC CureVac	$579.18M	2.08	$0.87 per share	6.16	$3.36 per share	1.60
GOSS Gossamer Bio	$114.70M	2.48	N/A	N/A	$0.13 per share	9.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$159.52M	$2.76	8.36	7.02	6.01	19.38%	22.20%	10.40%	8/6/2025 (Estimated)
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
CVAC CureVac	$175.50M	$0.92	5.85	N/A	N/A	35.44%	30.89%	25.54%	8/13/2025 (Estimated)
GOSS Gossamer Bio	-$56.53M	-$0.23	N/A	N/A	N/A	-41.12%	-128.98%	-15.52%	8/11/2025 (Estimated)

Latest GOSS, CVAC, CALT, and AMPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q1 2025	CVAC CureVac	-$0.16	-$0.24	-$0.08	-$0.24	$4.27 million	$0.94 million
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
4/10/2025	Q4 2024	CVAC CureVac	-$0.14	-$0.15	-$0.01	-$0.15	$6.40 million	$15.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.80	2.95	2.02
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
CVAC CureVac	0.05	7.65	7.64
GOSS Gossamer Bio	6.70	5.71	5.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
CALT Calliditas Therapeutics AB (publ)	2.83%
CVAC CureVac	17.26%
GOSS Gossamer Bio	81.23%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	27.50%
CALT Calliditas Therapeutics AB (publ)	2.20%
CVAC CureVac	2.15%
GOSS Gossamer Bio	6.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	2,028	47.14 million	34.18 million	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable
CVAC CureVac	880	224.34 million	219.52 million	Optionable
GOSS Gossamer Bio	180	227.30 million	212.07 million	Optionable

GOSS, CVAC, CALT, and AMPH Headlines

Recent News About These Companies

GOSS | Gossamer Bio Inc. Annual Income Statement - MarketWatch

June 26 at 5:50 AM | marketwatch.com

Gossamer Bio Completes Enrollment for Phase 3 PROSERA Study of PAH Drug Seralutinib

June 24, 2025 | msn.com

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

June 16, 2025 | businesswire.com

Cantor Fitzgerald Comments on Gossamer Bio FY2026 Earnings

June 10, 2025 | marketbeat.com

Two Sigma Investments LP Raises Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS)

June 8, 2025 | marketbeat.com

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | businesswire.com

Mackenzie Financial Corp Has $271,000 Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS)

June 5, 2025 | marketbeat.com

Two Sigma Advisers LP Grows Position in Gossamer Bio, Inc. (NASDAQ:GOSS)

June 1, 2025 | marketbeat.com

Millennium Management LLC Has $3.24 Million Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS)

June 1, 2025 | marketbeat.com

Earnings call transcript: Gossamer Bio exceeds Q1 2025 revenue forecasts

May 17, 2025 | uk.investing.com

Cantor Fitzgerald maintains Overweight on Gossamer Bio stock

May 17, 2025 | uk.investing.com

GOSSAMER BIO Earnings Results: $GOSS Reports Quarterly Earnings

May 17, 2025 | nasdaq.com

Gossamer Bio, Inc. (NASDAQ:GOSS) Q1 2025 Earnings Call Transcript

May 17, 2025 | msn.com

Q1 2025 Gossamer Bio Inc Earnings Call

May 16, 2025 | finance.yahoo.com

Gossamer Bio Inc (GOSS) Q1 2025 Earnings Call Highlights: Strategic Progress Amid Financial ...

May 16, 2025 | finance.yahoo.com

Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript

May 15, 2025 | seekingalpha.com

Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates

May 15, 2025 | zacks.com

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

May 15, 2025 | businesswire.com

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

May 7, 2025 | finance.yahoo.com

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 7, 2025 | businesswire.com

Gossamer Bio: Initiating Hold As Late‐Stage Data Nears Inflection

May 2, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS, CVAC, CALT, and AMPH Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$23.08 -0.10 (-0.43%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$23.49 +0.41 (+1.78%)

As of 06/27/2025 06:05 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 06/27/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

CureVac NASDAQ:CVAC

$5.38 -0.02 (-0.37%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.32 -0.06 (-1.21%)

As of 06/27/2025 06:59 PM Eastern

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Gossamer Bio NASDAQ:GOSS

$1.25 -0.05 (-3.85%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.30 +0.05 (+4.00%)

As of 06/27/2025 07:18 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time